NCT03317158 2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
Clinical Trials
229 trialsNCT06615752 2026-04-15
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Charles Drew University of Medicine and Science
Phase 1/2 Recruiting
NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT06931340 2026-04-07
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT02044354 2026-04-01
CABA-DOC
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT06734130 2026-04-01
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06704191 2026-03-30
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
Phase 1/2 Recruiting
NCT06282588 2026-03-19
THUNDER
Cancer Research Antwerp
Phase 2/3 Recruiting
NCT07428642 2026-03-18
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Completed
NCT07322263 2026-03-17
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
Phase 2 Not yet recruiting
NCT06488222 2026-03-11
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
University of Florida
Phase 2 Recruiting
NCT03574571 2026-02-27
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT05644041 2026-02-27
Intravesical Gem/Doce in Patients With NMIBC
University of Arizona
Phase 2 Recruiting
NCT03246347 2026-01-23
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT04126070 2026-01-22
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03456843 2026-01-21
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
Yale University
Phase 2 Active not recruiting
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03070886 2026-01-14
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Phase 2/3 Completed
NCT03258320 2026-01-12
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Shanghai Jiao Tong University School of Medicine
Phase 2/3 Recruiting
NCT07333066 2026-01-12
REINFORCE
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase 3 Not yet recruiting
NCT07316686 2026-01-05
Lutécio
Instituto do Cancer do Estado de São Paulo
Phase 1 Not yet recruiting
NCT07268794 2025-12-08
CONVERT-HB1
Fudan University
Phase 2 Not yet recruiting
NCT05189457 2025-12-04
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03575013 2025-12-03
A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
University of Iowa
Phase 1 Completed
NCT04386746 2025-11-17
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03582475 2025-11-12
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06929286 2025-10-30
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center
Phase 3 Recruiting
NCT06060587 2025-10-22
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Northwestern University
Phase 2 Withdrawn
NCT03069937 2025-10-15
Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.
Medical University of South Carolina
Phase 2 Completed
NCT01382706 2025-10-09
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
University of Southern California
Phase 2 Terminated
NCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
NCT06320067 2025-09-26
STAMPEDE2
University College, London
Phase 3 Recruiting
NCT05733351 2025-09-15
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Phase 1 Terminated
NCT07172685 2025-09-15
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
Qilu Hospital of Shandong University
Phase NA Recruiting
NCT04015622 2025-08-20
PROTRACT
British Columbia Cancer Agency
Phase 2 Active not recruiting
NCT07112209 2025-08-08
Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer
Zhujiang Hospital
Phase NA Enrolling by invitation
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT04343885 2025-07-11
UpFrontPSMA
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT03442556 2025-06-12
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
University of Washington
Phase 2 Terminated
NCT02913196 2025-05-23
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Active not recruiting
NCT03951831 2025-04-25
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Columbia University
Phase 2 Active not recruiting
NCT06864533 2025-04-24
PKUFH-GS5
Peking University First Hospital
Phase NA Recruiting
NCT03764540 2025-04-13
CABPOSTAAT
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Terminated
NCT06480110 2025-04-13
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
Rigshospitalet, Denmark
Phase 1/2 Recruiting
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT06652607 2025-03-12
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT05024734 2025-03-11
GAIN INST
Hospital Centre Biel/Bienne
Phase 2 Recruiting
NCT06446401 2025-03-04
Lead4Care
Uppsala University
Recruiting
NCT05676203 2025-02-17
ARASAFE
Jena University Hospital
Phase 3 Active not recruiting
NCT06496581 2024-12-20
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
Phase 3 Recruiting